- Conditions
- Advanced Solid Tumors
- Interventions
- MEDI9090, Durvalumab
- Biological
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 5
- States / cities
- Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 9,283
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Schizophrenia
- Interventions
- Aripiprazole
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 3
- States / cities
- Little Rock, Arkansas • San Diego, California • Austin, Texas
- Conditions
- Gastrointestinal Stromal Tumor (GIST)
- Interventions
- DCC-3009, Rabeprazole
- Drug
- Lead sponsor
- Deciphera Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 10
- States / cities
- Scottsdate, Arizona • La Jolla, California • Aurora, Colorado + 7 more
- Conditions
- Cardiovascular Diseases
- Interventions
- 18F-mFBG for intravenous administration
- Drug
- Lead sponsor
- Innervate Radiopharmaceuticals LLC (Formerly: Illumina Radiopharmaceuticals LLC)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy
- Interventions
- NKTR118 Formulation 1, NKTR118 Formulation 2, NKTR118 Formulation 3, NKTR118 Formulation 1a, NKTR118 Formulation 3a
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Healthy Participants
- Interventions
- Etrumadenant, Itraconazole
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 19 Years to 55 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021
- U.S. locations
- 1
- States / cities
- Lincoln, Nebraska
- Conditions
- Healthy Volunteers
- Interventions
- BMS-985521, Placebo
- Drug · Other
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 106 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Anaheim, California
- Conditions
- Metastases, Cancer
- Interventions
- ALIMTA, folic acid, multi-vitamins
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatocellular Carcinoma
- Interventions
- MM-141
- Drug
- Lead sponsor
- Merrimack Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 3
- States / cities
- Marietta, Georgia • Boston, Massachusetts • Detroit, Michigan
- Conditions
- Healthy Volunteers
- Interventions
- GLA-AF, GLA-SE, Squalene
- Drug · Other
- Lead sponsor
- Rockefeller University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Healthy Volunteer
- Interventions
- BIIB091
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Austin, Texas
- Conditions
- Small Cell Lung Cancer
- Interventions
- IMGN901, Carboplatin and Etoposide
- Drug
- Lead sponsor
- ImmunoGen, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 181 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 32
- States / cities
- Tucson, Arizona • Los Angeles, California • Orange, California + 23 more
- Conditions
- Non-Hodgkin's Lymphoma (disorder), Acute Lymphoid Leukemia, Disease (disorder)
- Interventions
- 1A46 Injection
- Drug
- Lead sponsor
- Chimagen Biosciences, Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Louisville, Kentucky • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Bacterial Infections
- Interventions
- Eravacycline (TP-434)
- Drug
- Lead sponsor
- Tetraphase Pharmaceuticals, Inc
- Industry
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Chicago, Illinois • Shreveport, Louisiana + 4 more
- Conditions
- Healthy Participants
- Interventions
- Casdatifan, Itraconazole, Phenytoin
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Solid Tumor, Adult
- Interventions
- CX-188
- Drug
- Lead sponsor
- CytomX Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Fairfax, Virginia
- Conditions
- Cutaneous Squamous Cell Carcinoma, Basal Cell Carcinoma
- Interventions
- IFx-Hu2.0
- Biological
- Lead sponsor
- TuHURA Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Brandon, Florida
- Conditions
- Colon Cancer, Colorectal Cancer
- Interventions
- EPO906, Celecoxib
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Cystic Fibrosis
- Interventions
- MRT5005, Normal saline
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 16
- States / cities
- Birmingham, Alabama • Denver, Colorado • Gainesville, Florida + 13 more
- Conditions
- Urinary Tract Infections
- Interventions
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1, Candidate UTI vaccine medium dose formulation 2, Candidate UTI vaccine high dose formulation 1, Candidate UTI vaccine high dose formulation 2, Candidate UTI vaccine HTD formulation 2, Placebo
- Combination Product
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 465 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 9
- States / cities
- Lenexa, Kansas • Covington, Louisiana • Secaucus, New Jersey + 6 more
- Conditions
- Oral Squamous Cell Carcinoma
- Interventions
- PRV111 (Cisplatin Transmucosal System)
- Drug
- Lead sponsor
- Privo Technologies
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 5
- States / cities
- Louisville, Kentucky • Cincinnati, Ohio • Houston, Texas
- Conditions
- Healthy
- Interventions
- PF-03463275, Placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Glendale, California
- Conditions
- Safety Issues
- Interventions
- Remimazolam, Alcohol
- Drug · Other
- Lead sponsor
- Paion UK Ltd.
- Industry
- Eligibility
- 21 Years to 45 Years · Female only
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Advanced Solid Tumors
- Interventions
- DT-7012, Immune checkpoint inhibitor
- Drug
- Lead sponsor
- Domain Therapeutics Australia Pty Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona